BEHIND THE NEWS: A peek inside Guidant-J&J-Boston Scientific drama
Corporate attorneys aren’t paid to write riveting prose. But the battle to buy Guidant Corp. is so drenched with drama that even the company’s normally bonedry regulatory filings make compelling reading these days. Here’s one gem in a recent filing: Just hours after Guidant sued Johnson & Johnson the morning of Nov. 7-an in-yourface tactic aimed at forcing J&J to close on its $25.4 billion purchase of the Indianapolis company-Guidant CEO Ron Dollens phoned a top J&J executive in an…